Arthur Lahr

Chief Executive Officer

Arthur Lahr is Chief Executive Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Chief Strategy Officer and member of the Management Committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011. Before that he was consultant at McKinsey & Company and engineer at Unilever. At present, Mr. Lahr also serves as a member of the supervisory board of Sanquin, the Dutch national plasma and blood product supplier. Mr. Lahr holds a Masters degree in Applied Physics from the University of Delft, The Netherlands, and an MBA from INSEAD, France.

Scott A. Holmes

Chief Financial Officer (from January 2019)

Mr. Holmes, who currently serves as Senior Vice President and CFO at Keryx Biopharmaceuticals, will join the Company following the completion of Keryx Biopharmaceuticals merger with Akebia Therapeutics, which is expected to close by the end of 2018. Prior to Keryx he was Senior Vice President of finance, investor relations and treasurer at AMAG Pharmaceuticals, during a period of high growth driven by acquisitions and public financings.


Prior to this he held senior roles at Molecular Biometrics, On-Q-ity and Dynogen. Mr. Holmes started his career at Ernst & Young, in both the Assurance and Transaction Services practices, and while at Ernst & Young he earned his Certified Public Accountant certificate in the Commonwealth of Massachusetts.  He holds a MS/MBA degree from Northeastern University and a BA in History from Middlebury College.

Mark Schaefer

Chief HR Officer

Mr. Mark Schaefer has 25 years of HR experience and joins from Aenova Holding, where he was Senior Vice President of Global HR. The Aenova Group is a global leader in the pharmaceutical and healthcare industries and one of the leading contract manufacturers in Europe. Prior to this Mr. Schaefer worked in senior global HR roles at West Pharmaceuticals, 3M, Sony and GE. He holds a Honors BA in Economics and Commerce as well as a Master’s degree in Industrial Relations from the University of Toronto. Mr. Schaefer is a Canadian citizen.

Jan Feijen

Chief Operations Officer

Jan Feijen is Chief Operations Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Vice President Manufacturing and Technical Operations, Platform Lead Vaccines and Advanced Therapies at Janssen (Pharmaceutical Companies of Johnson & Johnson). Prior to that he held various executive positions at Crucell, Avebe and Gist Brocades. Mr. Feijen holds a Masters degree in Applied Physics from the University of Delft, The Netherlands. 

Andrew Sandler

Chief Medical Officer

Andrew Sandler is the Chief Medical Officer at Kiadis Pharma. Prior to joining the company, he was Senior Vice President, Medical Affairs, at Medivation (now part of Pfizer). Prior to that he was CMO at Dendreon Pharmaceuticals and Spectrum Pharma. He has also held senior-level positions with several other leading biotechnology and pharmaceutical companies, including Bayer Healthcare, Berlex and Seattle Genetics. Dr. Sandler obtained his MD from Mount Sinai School of Medicine, New York and completed a fellowship in medical oncology at University of California San Francisco. A US citizen, Dr. Sandler is a board certified medical oncologist and has treated many patients with hematologic malignancies, including bone marrow transplant patients.

Amy Sullivan

Sr. Vice President, Corporate Affairs

Ms. Sullivan is a seasoned corporate affairs professional with more than 25 years of experience raising capital and building and managing corporate biotechnology and life sciences brands. Ms. Sullivan joins Kiadis from Keryx Biopharmaceuticals where she was senior vice president of corporate affairs, responsible for all aspects of investor relations, corporate communication, and public affairs, during a period of high growth, commercialization of the company’s first FDA-approved medicine and, ultimately, a merger. Prior to Keryx, Ms. Sullivan served as head of corporate communications and investor relations at AMAG Pharmaceuticals, Idenix Biopharmacueticals and Genencor International. Ms. Sullivan has her bachelor of science degree in business from Salem State University and her masters of business administration from Bentley University.

James Joy

General Counsel and Company Secretary

James Joy is General Counsel and Company Secretary of Kiadis Pharma.  Mr. Joy has over twenty years of blue chip experience as an international corporate lawyer advising multinational businesses in a variety of industries, having served as General Counsel at C-Map AS, TomTom NV and Navigator Asset Management and VP Legal at Royal Ahold NV.  Previously, Mr. Joy practiced law in New York and London with Latham & Watkins and Norton Rose Fulbright where he advised technology, media and industrial clients on corporate finance and mergers and acquisitions.  Mr. Joy holds a bachelor’s degree in Economics from Heriot-Watt University and a Juris Doctor degree from Tulane Law School.  Mr. Joy is a member of the New York State Bar.

Jonathan Sweeting

Head of Commercial Europe

Jonathan Sweeting is Head of Commercial Europe. Prior to joining Kiadis Pharma, he spent over five years at GSK in various leadership positions, most recently as Senior Vice President and Head of the Global Respiratory Franchise and previously in roles as General Manager Poland and Global Commercialization Leader for Respiratory Biologics. Mr. Sweeting joined GSK from AstraZeneca where he spent over eight years in global and local roles in the UK and Russia. Prior to that he was at Accenture for five years. Mr. Sweeting holds an MA (Hons) degree in Chemistry from the University of Cambridge and an MBA from INSEAD. Mr. Sweeting is a British citizen.

Marcel Zwaal

Head of Corporate Development

Marcel Zwaal is Head of Corporate Development. Prior to joining Kiadis Pharma, he was CEO of Hubrecht Organoid Technologies. Previously, Mr. Zwaal worked in Corporate Development at Galapagos, served as CEO of cell therapy biotech startup DCPrime and held several senior management positions at Crucell in finance and business development prior to its acquisition by Johnson & Johnson in 2011. Mr. Zwaal has over 20 years’ experience in finance and business, 10 years of which has focused on medical innovation and biotechnology. He holds an Executive Master of Finance and Control degree and a Finance BA Master’s degree from Vrije Universiteit Amsterdam. Mr. Zwaal is a Dutch citizen.